Company Analysis Walvax Biotechnology Co., Ltd.
1. Summary
Disadvantages
- Price (9.9 Β₯) is higher than fair price (7.07 Β₯)
- Dividends (0.04%) are below the sector average (1.83%).
- The stock's return over the last year (-60.75%) is lower than the sector average (-36.11%).
- The company's current efficiency (ROE=9.93%) is lower than the sector average (ROE=11.95%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Walvax Biotechnology Co., Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.5% | -4.6% | -1.1% |
| 90 days | -19.1% | -16% | 16.6% |
| 1 year | -60.7% | -36.1% | 42.9% |
300142 vs Sector: Walvax Biotechnology Co., Ltd. has significantly underperformed the "Healthcare" sector by -24.63% over the past year.
300142 vs Market: Walvax Biotechnology Co., Ltd. has significantly underperformed the market by -103.65% over the past year.
Stable price: 300142 is not significantly more volatile than the rest of the market on "Shenzhen Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 300142 with weekly volatility of -1.17% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (9.9 Β₯) is higher than the fair price (7.07 Β₯).
Price is higher than fair: The current price (9.9 Β₯) is 28.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (48.3) is lower than that of the sector as a whole (69.4).
P/E vs Market: The company's P/E (48.3) is lower than that of the market as a whole (63.57).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.51) is higher than that of the sector as a whole (3.96).
P/BV vs Market: The company's P/BV (4.51) is higher than that of the market as a whole (3.79).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (7.91) is higher than that of the sector as a whole (6.51).
P/S vs Market: The company's P/S indicator (7.91) is higher than that of the market as a whole (5.87).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (31.91) is higher than that of the sector as a whole (11.85).
EV/Ebitda vs Market: The company's EV/Ebitda (31.91) is higher than that of the market as a whole (25.54).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -2.81% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-2.81%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (9.93%) is lower than that of the sector as a whole (11.95%).
ROE vs Market: The company's ROE (9.93%) is higher than that of the market as a whole (9.38%).
5.5. ROA
ROA vs Sector: The company's ROA (4.95%) is lower than that of the sector as a whole (5.4%).
ROA vs Market: The company's ROA (4.95%) is higher than that of the market as a whole (3.95%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.04% is below the average for the sector '1.83%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.04% has been steadily paid over the past 7 years, DSI=0.79.
Weak dividend growth: The company's dividend yield 0.04% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (5.02%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
